ATE457985T1 - Substituierte pyrazinonderivate zur verwendung als arzneimittel - Google Patents
Substituierte pyrazinonderivate zur verwendung als arzneimittelInfo
- Publication number
- ATE457985T1 ATE457985T1 AT07821116T AT07821116T ATE457985T1 AT E457985 T1 ATE457985 T1 AT E457985T1 AT 07821116 T AT07821116 T AT 07821116T AT 07821116 T AT07821116 T AT 07821116T AT E457985 T1 ATE457985 T1 AT E457985T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- anxiety
- pyrazinone derivatives
- mood
- substituted pyrazinone
- Prior art date
Links
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical class OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06122173 | 2006-10-12 | ||
| PCT/EP2007/060748 WO2008043775A1 (en) | 2006-10-12 | 2007-10-10 | Substituted pyrazinone derivatives for use as a medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE457985T1 true ATE457985T1 (de) | 2010-03-15 |
Family
ID=37781925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07821116T ATE457985T1 (de) | 2006-10-12 | 2007-10-10 | Substituierte pyrazinonderivate zur verwendung als arzneimittel |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100105694A1 (de) |
| EP (1) | EP2091942B1 (de) |
| JP (1) | JP2010505908A (de) |
| CN (1) | CN101522660A (de) |
| AT (1) | ATE457985T1 (de) |
| AU (1) | AU2007306382A1 (de) |
| CA (1) | CA2659923A1 (de) |
| DE (1) | DE602007004881D1 (de) |
| DK (1) | DK2091942T3 (de) |
| ES (1) | ES2339998T3 (de) |
| IL (1) | IL198072A0 (de) |
| MX (1) | MX2009003849A (de) |
| RU (1) | RU2009117653A (de) |
| WO (1) | WO2008043775A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
| DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
| DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
| FR2976287B1 (fr) | 2011-06-09 | 2013-07-05 | Pf Medicament | Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN108178759B (zh) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | 一种α-肾上腺素受体拮抗剂的合成方法 |
| KR20230074209A (ko) * | 2020-09-23 | 2023-05-26 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 알파 2 아드레날린 수용체 안타고니스트 |
| CN119350255B (zh) * | 2024-10-21 | 2025-12-09 | 海南大学 | 一种酮衍生物及其合成方法和用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1534391B1 (de) * | 2002-07-19 | 2007-02-14 | Biovitrum AB | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen |
-
2007
- 2007-10-10 DE DE602007004881T patent/DE602007004881D1/de active Active
- 2007-10-10 EP EP07821116A patent/EP2091942B1/de active Active
- 2007-10-10 CN CNA2007800380865A patent/CN101522660A/zh active Pending
- 2007-10-10 ES ES07821116T patent/ES2339998T3/es active Active
- 2007-10-10 AU AU2007306382A patent/AU2007306382A1/en not_active Abandoned
- 2007-10-10 DK DK07821116.6T patent/DK2091942T3/da active
- 2007-10-10 AT AT07821116T patent/ATE457985T1/de active
- 2007-10-10 JP JP2009531832A patent/JP2010505908A/ja not_active Withdrawn
- 2007-10-10 CA CA002659923A patent/CA2659923A1/en not_active Abandoned
- 2007-10-10 US US12/445,243 patent/US20100105694A1/en not_active Abandoned
- 2007-10-10 RU RU2009117653/04A patent/RU2009117653A/ru not_active Application Discontinuation
- 2007-10-10 WO PCT/EP2007/060748 patent/WO2008043775A1/en not_active Ceased
- 2007-10-10 MX MX2009003849A patent/MX2009003849A/es unknown
-
2009
- 2009-04-07 IL IL198072A patent/IL198072A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2091942T3 (da) | 2010-05-17 |
| JP2010505908A (ja) | 2010-02-25 |
| CN101522660A (zh) | 2009-09-02 |
| RU2009117653A (ru) | 2010-11-20 |
| MX2009003849A (es) | 2009-04-23 |
| IL198072A0 (en) | 2009-12-24 |
| DE602007004881D1 (de) | 2010-04-01 |
| WO2008043775A1 (en) | 2008-04-17 |
| AU2007306382A1 (en) | 2008-04-17 |
| EP2091942B1 (de) | 2010-02-17 |
| EP2091942A1 (de) | 2009-08-26 |
| US20100105694A1 (en) | 2010-04-29 |
| CA2659923A1 (en) | 2008-04-17 |
| ES2339998T3 (es) | 2010-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
| MX2009005908A (es) | Derivados novedosos de diaza-espiro-piridinona sustituidos para usarse en las enfermedades mediadas por la hormona concentradora de melanina 1. | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| HRP20041179B1 (hr) | Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti | |
| CY1110711T1 (el) | Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3 | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
| ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
| DE602009001212D1 (de) | Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung | |
| DE602005016836D1 (de) | Chotischer und anxiolytischer aktivität | |
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
| WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
| ATE440826T1 (de) | Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2091942 Country of ref document: EP |